ClinicalTrials.gg
CompletedNCT01288469Updated Sep 24, 2015Results posted

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

A Phase 2 interventional study of Alirocumab and Placebo (for alirocumab) in Hypercholesterolemia, sponsored by Sanofi. Completed at 20 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-24.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
26th of 43
92 · median 107
Started
2011
with 6 others
Phase 2
9 of 43
none open now
Registered
3rd of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 26th largest by enrollment, is one of 7 that started in 2011, is one of 9 in phase 2, and was the 3rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo when co-administered with 80 mg of atorvastatin after 8 weeks of treatment in participants with LDL-C ≥ 100mg/dL (≥ 2.59 mmol/L) on atorvastatin 10 mg.

Secondary Objectives:

  • To evaluate the effects of alirocumab on other lipid levels in comparison with placebo, when co-administered with 80 mg of atorvastatin after 8 weeks of treatment.
  • To evaluate the efficacy of alirocumab when co-administered with a high dose of atorvastatin (80 mg) versus atorvastatin 10 mg.
  • To evaluate the safety and tolerability of alirocumab when co-administered with 2 different doses of atorvastatin.
  • To evaluate the development of anti-alirocumab antibodies.
  • To evaluate the pharmacokinetics of alirocumab.
Read the detailed description

The duration of study participation depended on the status of the patient at screening:

  • For participants receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening, the study participation was to be approximately 17 weeks including a screening period of 1 week, a double-blind treatment period of 8 weeks and a follow-up period of 8 weeks.
  • For participants receiving a lipid lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive participants, the study participation was to be approximately 23 weeks with a screening period of 1 week, a run-in treatment period with atorvastatin 10 mg of 6 weeks, a double-blind treatment period of 8 weeks and a follow-up period of 8 weeks.
03

Conditions studied

  • Hypercholesterolemia

Keywords

  • 10020603
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants receiving a lipid-lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive participants with primary hypercholesterolemia if they are likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the end of the 6-week run-in treatment period on atorvastatin therapy

OR

  • Participants with primary hypercholesterolemia treated with stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening and likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the screening visit.

Exclusion criteria

Exclusion criteria:

  1. LDL-C \< 100 mg/dL (\< 2.59 mmol/L) at Week -1 (V1):

    • After the run-in period on atorvastatin 10 mg for participants receiving a lipid lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to the screening period, or drug naive participants.

    OR

    • At the first visit for participants who are being treated with atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening visit.
  2. Participants not previously instructed on a cholesterol-lowering diet.
  3. Participants with type 1 diabetes.
  4. Participants with type 2 diabetes treated with insulin.
  5. Participants with type 2 diabetes and with an ≥ 8.5% at screening visit (considered poorly controlled).
  6. Laboratory findings measured before randomization:

    • Triglycerides (TG) > 350 mg/dL (> 3.95 mmol/L) at screening visit.
    • Positive serum or urine pregnancy test in females of .
  7. Pregnant or breast-feeding women.
  8. Women of childbearing potential with no effective method.

The above information is not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Placebo comparator
    Placebo + Atorvastatin 80 mg

    Placebo (for alirocumab) subcutaneous (SC) administration every 2 weeks (Q2W) in combination with atorvastatin 80 mg orally once daily for 8 weeks.

    Drug: Placebo (for alirocumab) · Drug: Atorvastatin

  • Experimental
    Alirocumab + Atorvastatin 10 mg

    Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 10 mg orally once daily for 8 weeks.

    Drug: Alirocumab · Drug: Atorvastatin · Drug: Placebo (for atorvastatin)

  • Experimental
    Alirocumab + Atorvastatin 80 mg

    Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 80 mg orally once daily for 8 weeks.

    Drug: Alirocumab · Drug: Atorvastatin

Interventions

  • One subcutaneous (SC) injection in the abdomen only.

    Also known as: SAR236553, REGN727

  • DrugPlacebo (for alirocumab)

    One SC injection in the abdomen only.

  • Over-encapsulated tablet orally once daily in the evening with dinner.

  • DrugPlacebo (for atorvastatin)

    One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis

    Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 8 data were imputed by last observation carried forward \[LOCF\] method.

    Time frame: From Baseline to Week 8 (LOCF)

Secondary outcomes

  1. Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 8 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From baseline to Week 8 (LOCF)

  2. Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 8 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From baseline to Week 8 (LOCF)

  3. Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 8 - On-treatment Analysis

    Time frame: Week 8 (LOCF)

  4. Percent Change From Baseline in Total Cholesterol, Fasting Triglycerides, Non-high-Density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B (Apo-B) and Lipoprotein(a) at Week 8 - On-treatment Analysis

    Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range).

    Time frame: From baseline to Week 8 (LOCF)

  5. Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 8 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 8 (LOCF)

  6. Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 8 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA as for primary endpoint.

    Time frame: From Baseline to Week 8 (LOCF)

07

Results

Posted Sep 24, 2015

Participant flow

The study was conducted at 20 centers in the United States of America. Overall, 214 participants were screened between January 2011 and April 2011. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestonePlacebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
Started313130
Treated313130
Completed242828
Not completed732
Withdrew: Adverse event411
Withdrew: Poor compliance to protocol010
Withdrew: Participant moved100
Withdrew: Consent withdrawn by subject111
Withdrew: Exclusion criteria finally met100

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis

Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 8 data were imputed by last observation carried forward \[LOCF\] method.

Time frame:
From Baseline to Week 8 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis
percent changePlacebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis-17.3 ± 3.5-66.2 ± 3.5-73.2 ± 3.5
Statistical analysis
  • Placebo + Atorvastatin 80 mg vs Alirocumab + Atorvastatin 80 mg · ANCOVA · p = <0.0001 (Threshold for significance ≤0.05.) · Ls mean difference: -55.82 · 95% CI -65.62 to -46.03Alirocumab vs. placebo
SecondaryAbsolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 8 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From baseline to Week 8 (LOCF)
Reported as:
Least squares mean · mmol/L
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 8 - On-treatment Analysis
mmol/LPlacebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 8 - On-treatment Analysis-0.56 ± 0.11-2.09 ± 0.11-2.31 ± 0.11
SecondaryAbsolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 8 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From baseline to Week 8 (LOCF)
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 8 - On-treatment Analysis
mg/dLPlacebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 8 - On-treatment Analysis-21.5 ± 4.2-80.7 ± 4.2-89.3 ± 4.1
SecondaryPercentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 8 - On-treatment Analysis
Time frame:
Week 8 (LOCF)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 8 - On-treatment Analysis
percentage of participantsPlacebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
LDL-C < 100 mg/dL (2.59 mmol/L)51.7100.0100.0
LDL-C < 70 mg/dL (1.81 mmol/L)17.296.690.0
SecondaryPercent Change From Baseline in Total Cholesterol, Fasting Triglycerides, Non-high-Density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B (Apo-B) and Lipoprotein(a) at Week 8 - On-treatment Analysis

Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range).

Time frame:
From baseline to Week 8 (LOCF)
Reported as:
Median · percent change
Percent Change From Baseline in Total Cholesterol, Fasting Triglycerides, Non-high-Density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B (Apo-B) and Lipoprotein(a) at Week 8 - On-treatment Analysis
percent changePlacebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
Total Cholesterol (n=29, 29, 30)-16.6 (-25.1 to -3.2)-40.5 (-44.8 to -36.0)-47.2 (-51.5 to -37.8)
Fasting Triglycerides (n=29, 29, 30)-11.9 (-30.4 to 14.3)-4.0 (-30.5 to 17.4)-24.7 (-40.3 to -4.4)
Non-HDL-C (n= 29, 29, 30)-22.3 (-31.4 to -3.7)-58.3 (-63.9 to -50.2)-63.9 (-73.9 to -56.1)
Apo-B (n = 29, 28, 29)-12.0 (-23.6 to -3.5)-54.4 (-60.2 to -48.3)-58.0 (-67.1 to -46.1)
Lipoprotein(a) (n= 29, 28, 29)-2.7 (-19.5 to 16.7)-34.7 (-50.0 to -24.7)-31.0 (-50.0 to -15.4)
SecondaryPercent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 8 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 8 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 8 - On-treatment Analysis
percent changePlacebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 8 - On-treatment Analysis-3.6 ± 2.32.6 ± 2.35.8 ± 2.3
SecondaryAbsolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 8 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA as for primary endpoint.

Time frame:
From Baseline to Week 8 (LOCF)
Reported as:
Median · ratio
Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 8 - On-treatment Analysis
ratioPlacebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 8 - On-treatment Analysis-0.03 (-0.12 to 0.08)-0.34 (-0.44 to -0.27)-0.36 (-0.40 to -0.29)

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 16) regardless of seriousness or relationship to investigational medicianal product (IMP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Atorvastatin 80mg—0/31 (0%)13/31 (41.9%)
Alirocumab + Atorvastatin 10 mg—0/31 (0%)4/31 (12.9%)
Alirocumab + Atorvastatin 80 mg—1/30 (3.3%)10/30 (33.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo + Atorvastatin 80mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
DehydrationMetabolism and nutrition disorders0/310/311/30
Most frequent other events
Most frequent other events
EventPlacebo + Atorvastatin 80mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mg
Pain in extremityMusculoskeletal and connective tissue disorders5/310/311/30
DizzinessNervous system disorders0/310/313/30
HeadacheNervous system disorders2/310/313/30
DiarrhoeaGastrointestinal disorders3/311/313/30
Accidental overdoseInjury, poisoning and procedural complications0/312/312/30
Upper respiratory tract infectionInfections and infestations2/312/311/30
Injection site pruritusGeneral disorders2/310/311/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mgTotal
Mean55.3 ± 10.357.9 ± 10.057.6 ± 9.356.9 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mgTotal
Female18172055
Male13141037
Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L
Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L(mmol/L)Placebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mgTotal
Mean3.138 ± 0.4693.101 ± 0.4023.288 ± 0.5643.174 ± 0.484
LDL-C in mg/dL
LDL-C in mg/dL(mg/dL)Placebo + Atorvastatin 80 mgAlirocumab + Atorvastatin 10 mgAlirocumab + Atorvastatin 80 mgTotal
Mean121.2 ± 18.1119.7 ± 15.5126.9 ± 21.8122.6 ± 18.7
08

Study locations

20 sites
  • Investigational Site Number 840616
    Mesa, Arizona 85206, United States
  • Investigational Site Number 840601
    Tucson, Arizona 85710, United States
  • Investigational Site Number 840610
    Los Angeles, California 90057, United States
  • Investigational Site Number 840608
    Newport Beach, California 92660, United States
  • Investigational Site Number 840603
    Doral, Florida 33166, United States
  • Investigational Site Number 840611
    Jacksonville, Florida 32223, United States
  • Investigational Site Number 840618
    Jupiter, Florida 33458, United States
  • Investigational Site Number 840612
    Miami, Florida 33138, United States
  • Investigational Site Number 840614
    Miami, Florida 33138, United States
  • Investigational Site Number 840607
    St. Petersburg, Florida 33609, United States
  • Investigational Site Number 840605
    Chicago, Illinois 60610, United States
  • Investigational Site Number 840619
    Chicago, Illinois 60610, United States
  • Investigational Site Number 840604
    Edison, New Jersey 08817, United States
  • Investigational Site Number 840606
    Rochester, New York 14609, United States
  • Investigational Site Number 840615
    Cincinnati, Ohio 45219, United States
  • Investigational Site Number 840617
    Cincinnati, Ohio 45219, United States
  • Investigational Site Number 840602
    Eugene, Oregon 97404, United States
  • Investigational Site Number 840621
    Richmond, Virginia 23227, United States
  • Investigational Site Number 840609
    Olympia, Washington 98502, United States
  • Investigational Site Number 840613
    Oregon, Wisconsin 53575, United States
09

References and documents

Publications

  • Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012 Nov 15;367(20):1891-900. doi: 10.1056/NEJMoa1201832. Epub 2012 Oct 31. PubMed 23113833 ↗
  • Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014 Sep 1;114(5):711-5. doi: 10.1016/j.amjcard.2014.05.060. Epub 2014 Jun 18. PubMed 25060413 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Toth PP, Hamon SC, Jones SR, Martin SS, Joshi PH, Kulkarni KR, Banerjee P, Hanotin C, Roth EM, McKenney JM. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis. 2016 Feb 13;15:28. doi: 10.1186/s12944-016-0197-4. PubMed 26872608 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 4 years after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2011
First posted
Feb 2, 2011
Start
Jan 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results delay requested
Dec 12, 2012
Results first posted
Sep 24, 2015
Last update
Sep 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01288469
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 2, 2011
Start date
Jan 2011
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Sep 24, 2015
Last update
Sep 24, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion